Tower Research Capital LLC TRC Has $958,000 Holdings in Eli Lilly And Co (LLY)

Tower Research Capital LLC TRC reduced its position in shares of Eli Lilly And Co (NYSE:LLY) by 69.7% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 8,932 shares of the company’s stock after selling 20,513 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Eli Lilly And Co were worth $958,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Perigon Wealth Management LLC bought a new stake in shares of Eli Lilly And Co in the third quarter worth approximately $224,000. Ancora Advisors LLC grew its stake in shares of Eli Lilly And Co by 95.8% in the third quarter. Ancora Advisors LLC now owns 6,177 shares of the company’s stock worth $663,000 after acquiring an additional 3,022 shares during the period. SVA Plumb Wealth Management LLC grew its stake in shares of Eli Lilly And Co by 17.0% in the third quarter. SVA Plumb Wealth Management LLC now owns 3,656 shares of the company’s stock worth $392,000 after acquiring an additional 532 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Eli Lilly And Co by 8.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 83,405 shares of the company’s stock worth $8,947,000 after acquiring an additional 6,228 shares during the period. Finally, Eaton Vance Management grew its stake in shares of Eli Lilly And Co by 0.6% in the third quarter. Eaton Vance Management now owns 3,188,420 shares of the company’s stock worth $342,149,000 after acquiring an additional 17,848 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

LLY opened at $118.52 on Tuesday. The company has a current ratio of 1.91, a quick ratio of 1.53 and a debt-to-equity ratio of 0.83. The company has a market capitalization of $125.68 billion, a P/E ratio of 27.69, a price-to-earnings-growth ratio of 1.85 and a beta of 0.31. Eli Lilly And Co has a 12-month low of $73.69 and a 12-month high of $118.71.

Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings data on Tuesday, November 6th. The company reported $1.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.35 by $0.04. The company had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. The firm’s revenue was up 7.1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.05 earnings per share. On average, equities research analysts predict that Eli Lilly And Co will post 5.58 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, December 10th. Shareholders of record on Thursday, November 15th will be issued a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a yield of 1.90%. The ex-dividend date is Wednesday, November 14th. Eli Lilly And Co’s dividend payout ratio is currently 52.57%.

In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 180,000 shares of Eli Lilly And Co stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $106.76, for a total transaction of $19,216,800.00. Following the transaction, the insider now owns 119,832,753 shares of the company’s stock, valued at $12,793,344,710.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Eli & Co Lilly sold 10,059 shares of Eli Lilly And Co stock in a transaction that occurred on Wednesday, September 12th. The shares were sold at an average price of $14.83, for a total transaction of $149,174.97. Following the transaction, the insider now directly owns 3,894,318 shares in the company, valued at approximately $57,752,735.94. The disclosure for this sale can be found here. Insiders have sold 2,127,300 shares of company stock worth $166,973,853 in the last ninety days. Insiders own 0.11% of the company’s stock.

A number of equities analysts recently issued reports on the stock. SunTrust Banks raised their price objective on shares of Eli Lilly And Co from $105.00 to $123.00 and gave the stock a “buy” rating in a report on Monday, October 1st. Zacks Investment Research downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Friday, September 28th. Cantor Fitzgerald reissued a “buy” rating and issued a $128.00 price objective on shares of Eli Lilly And Co in a report on Wednesday, October 17th. Wolfe Research assumed coverage on shares of Eli Lilly And Co in a report on Tuesday, October 23rd. They issued a “market perform” rating and a $119.00 price objective on the stock. Finally, TheStreet downgraded shares of Eli Lilly And Co from a “b” rating to a “c+” rating in a report on Friday, August 24th. Ten equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Eli Lilly And Co has a consensus rating of “Buy” and a consensus price target of $111.24.

COPYRIGHT VIOLATION NOTICE: “Tower Research Capital LLC TRC Has $958,000 Holdings in Eli Lilly And Co (LLY)” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.com-unik.info/2018/12/04/tower-research-capital-llc-trc-has-958000-holdings-in-eli-lilly-and-co-lly.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: Stock Selection – What is cash flow?

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit